Xerxes Pundole1, Natalia V Zamora2, Harish Siddhanamatha3, Heather Lin4, Jean Tayar1, Leung Cheuk Hong4, Liang Li4, Maria E Suarez-Almazor5. 1. Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. 2. Sección Reumatología, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina. 3. Department of Data Integrity and Analytics, Augusta University Medical Center, Augusta, Georgia. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. msalmazor@mdanderson.org.
Abstract
INTRODUCTION: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) interfere with the immune system and could theoretically increase risk of malignancies. However, recent evidence has not substantiated such concerns and physicians are less reluctant in treating patients with underlying cancer with such bDMARDs. We aimed to understand the current utilization patterns of bDMARDs for the treatment of rheumatoid arthritis (RA) in cancer patients. METHODS: We performed a retrospective cohort study of patients with prevalent RA and cancer initially seen at MD Anderson Cancer Center between 2002 and 2014. A cohort of cancer patients was identified from the tumor registry, and patients with RA were identified through ICD-9 codes, followed by review of electronic medical records. We included patients 18 years and older, with a cancer diagnosis, and a diagnosis of RA by a rheumatologist. Patients were followed until 2016. RESULTS: We identified 431 patients with RA and cancer that met our inclusion criteria. Overall, 111 (26%) received bDMARDs after their cancer diagnosis; of these, 60 (54%) had received bDMARDs prior to their cancer diagnosis and continued to receive this therapy following their diagnosis. Thirteen (22%) switched to a different bDMARD, and the rest continued to receive the same agent after their cancer diagnosis. Of all patients on a bDMARD, 91 (82%) received tumor necrosis factor inhibitors (TNFi). CONCLUSIONS: The treatment landscape of patients with a history of cancer and RA is changing. Future studies evaluating the safety of bDMARDs in patients with a recent history of cancer or with active cancer are needed. Part of the data of this project was presented as a poster at the 2016 American College of Rheumatology annual meeting. Zamora NV, Siddhanamatha H, Barbo A, Tayar J, Lin H, Suarez-Almazor M. Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer [abstract].Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/utilization-of-biologic-therapy-in-patients-with-rheumatoid-arthritis-and-cancer/. Accessed September 30, 2019. Key Points • One in four patients with RA and concomitant cancer received bDMARDs, including TNFi, after their cancer diagnosis, at our institution. • Half of the patients with RA and cancer who received bDMARDs had initiated therapy prior to the cancer diagnosis, continuing thereafter.
INTRODUCTION: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) interfere with the immune system and could theoretically increase risk of malignancies. However, recent evidence has not substantiated such concerns and physicians are less reluctant in treating patients with underlying cancer with such bDMARDs. We aimed to understand the current utilization patterns of bDMARDs for the treatment of rheumatoid arthritis (RA) in cancerpatients. METHODS: We performed a retrospective cohort study of patients with prevalent RA and cancer initially seen at MD Anderson Cancer Center between 2002 and 2014. A cohort of cancerpatients was identified from the tumor registry, and patients with RA were identified through ICD-9 codes, followed by review of electronic medical records. We included patients 18 years and older, with a cancer diagnosis, and a diagnosis of RA by a rheumatologist. Patients were followed until 2016. RESULTS: We identified 431 patients with RA and cancer that met our inclusion criteria. Overall, 111 (26%) received bDMARDs after their cancer diagnosis; of these, 60 (54%) had received bDMARDs prior to their cancer diagnosis and continued to receive this therapy following their diagnosis. Thirteen (22%) switched to a different bDMARD, and the rest continued to receive the same agent after their cancer diagnosis. Of all patients on a bDMARD, 91 (82%) received tumornecrosis factor inhibitors (TNFi). CONCLUSIONS: The treatment landscape of patients with a history of cancer and RA is changing. Future studies evaluating the safety of bDMARDs in patients with a recent history of cancer or with active cancer are needed. Part of the data of this project was presented as a poster at the 2016 American College of Rheumatology annual meeting. Zamora NV, Siddhanamatha H, Barbo A, Tayar J, Lin H, Suarez-Almazor M. Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer [abstract].Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/utilization-of-biologic-therapy-in-patients-with-rheumatoid-arthritis-and-cancer/. Accessed September 30, 2019. Key Points • One in four patients with RA and concomitant cancer received bDMARDs, including TNFi, after their cancer diagnosis, at our institution. • Half of the patients with RA and cancer who received bDMARDs had initiated therapy prior to the cancer diagnosis, continuing thereafter.
Authors: Daniel E Furst; Edward Clark Keystone; Alexander K So; Jürgen Braun; Ferry C Breedveld; Gerd R Burmester; Fabrizio De Benedetti; Thomas Dörner; Paul Emery; Roy Fleischmann; Allan Gibofsky; J R Kalden; Arthur Kavanaugh; Bruce Kirkham; Philip Mease; A Rubbert-Roth; Joachim Sieper; Nora G Singer; Josef S Smolen; Piet L C M Van Riel; Michael H Weisman; Kevin L Winthrop Journal: Ann Rheum Dis Date: 2013-04 Impact factor: 19.103
Authors: Pepijn A Borggreven; Dirk J Kuik; Johannes A Langendijk; Patricia Doornaert; Remco de Bree; C René Leemans Journal: Oral Oncol Date: 2005-04 Impact factor: 5.337
Authors: Kalle Jyri Aaltonen; Jaana Tuulikki Joensuu; Liisa Virkki; Tuulikki Sokka; Pasi Aronen; Heikki Relas; Heikki Valleala; Vappu Rantalaiho; Laura Pirilä; Kari Puolakka; Tea Uusitalo; Marja Blom; Yrjö Tapio Konttinen; Dan Nordström Journal: J Rheumatol Date: 2015-01-15 Impact factor: 4.666
Authors: Lucía Silva-Fernández; Mark Lunt; Lianne Kearsley-Fleet; Kath D Watson; William G Dixon; Deborah P M Symmons; Kimme L Hyrich Journal: Rheumatology (Oxford) Date: 2016-08-22 Impact factor: 7.580
Authors: Louise K Mercer; Johan Askling; Pauline Raaschou; William G Dixon; Lene Dreyer; Merete Lund Hetland; Anja Strangfeld; Angela Zink; Xavier Mariette; Axel Finckh; Helena Canhao; Florenzo Iannone; Jakub Zavada; Jacques Morel; Jacques-Eric Gottenberg; Kimme L Hyrich; Joachim Listing Journal: Ann Rheum Dis Date: 2016-06-15 Impact factor: 19.103
Authors: Maria Antonietta Barbieri; Giuseppe Cicala; Paola Maria Cutroneo; Elisabetta Gerratana; Caterina Palleria; Caterina De Sarro; Ada Vero; Luigi Iannone; Antonia Manti; Emilio Russo; Giovambattista De Sarro; Fabiola Atzeni; Edoardo Spina Journal: J Clin Med Date: 2020-04-24 Impact factor: 4.241